Ansley M. Nemeth

Expanding the Utility of Colistin Adjuvants To Encompass Next-Generation Polymyxins against Polymyxin-Resistant Acinetobacter baumannii and Klebsiella pneumoniae

Abstract Current treatment options for multidrug-resistant (MDR) Gram-negative infections are effectively limited to last-resort antibiotics, such as the polymyxins. Clinical use of polymyxins remains limited due to significant nephrotoxic side effects, and is further limited as...